PILA PHARMA
1.18 SEK
+0.85 %
Less than 1K followers
PILA
First North Stockholm
Biotechnology & Pharmaceuticals
Health Care
Overview
Financials & Estimates
Ownership
Dividend
+0.85 %
-1.67 %
-42.72 %
-48.13 %
-43.41 %
-61.09 %
-45.89 %
-
-84.90 %
PILA PHARMA is a clinical stage biotechnology company based in Malmö, Sweden. The company is developing novel oral therapeutics for globally common metabolic diseases such as Diabetes, Obesity and Cardiovascular diseases as well as therapeutics for Pain treatment. The company has obtained an orphan drug designation in the United States for the rare disease Erythromelalgia. The company is specializing in development of pharmaceutical drugs based on TRPV1-antagonists.
Read moreMarket cap
53.9M SEK
Turnover
13.64K SEK
Revenue
1.13M
EBIT %
-698.23 %
P/E
-
Dividend yield-%
-
Revenue and EBIT-%
Revenue M
EBIT-% (adj.)
EPS and dividend
EPS (adj.)
Dividend %
Financial calendar
22.4
2026
General meeting '26
27.8
2026
Interim report Q2'26
25.2
2027
Annual report '26
All
Research
Webcasts
Press releases
ShowingAll content types
PILA PHARMA: TO2 WARRANTS CONVERTED, SHARES ARE NOW TRADABLE - CEO & FOUNDER'S PARTICIPATION DISCLOSED
BioStock: Pila Pharma boosts financial runway and fully funds clinical obesity study
Join Inderes community
Don't miss out - create an account and get all the possible benefits
Inderes account
Followings and notifications on followed companies
Analyst comments and recommendations
Stock comparison tool & other popular tools